Effects of a hemostatic powder hemospray on coagulation and clot formation

 

 Buy Article Permissions and Reprints

Background and study aims: Hemospray (Cook Medical Inc., Winston-Salem, North Carolina, USA) is a novel, hemostatic, powder spray that has been developed for gastrointestinal use. The powder is thought to achieve hemostasis by concentrating clotting factors and forming a mechanical plug on the injured blood vessel. However, no detailed studies on the hemostatic mode of action have been performed. The aim of this study was to examine the effects of Hemospray on coagulation and clot formation both in vitro and in vivo.

Materials and methods: Recalcification time, thromboelastometry using EXTEM and INTEM assays, and plasma coagulation tests (activated partial thromboplastin time and prothrombin time) were carried out on blood samples mixed with Hemospray, and compared with talcum powder (negative control) and kaolin (positive control) at 1 mg/mL and 10 mg/mL. Scanning electron microscopy (SEM) and light microscopy were performed on in vitro thrombi and on gastric thrombi from an animal model of gastrointestinal hemorrhage treated with Hemospray.

Results: The median recalcification time of whole blood was 187.5 seconds. The addition of 1 mg/mL and 10 mg/mL Hemospray significantly shortened this time (median 60 and 45 seconds, respectively; P < 0.05). The median clotting time of whole blood, measured using the INTEM assay, was 160 seconds (interquartile range [IQR] 159 – 176.5) and this was also significantly reduced by the addition of Hemospray (91 seconds [IQR 84 – 102]; P = 0.005). The plasma prothrombin time of 11.6 seconds was significantly reduced by Hemospray (9.5 seconds; P = 0.011). SEM of in vivo clots demonstrated that Hemospray rapidly interacted with whole blood, forming one confluent mass over the bleeding site. In sufficient amounts, Hemospray was able to deform and pack erythrocytes.

Conclusions: Hemospray covered the bleeding site and enhanced clot formation in vivo, and shortened coagulation time in vitro. Elaboration of these unique properties in clinical practice will help to optimize future endoscopic hemostasis with Hemospray.

• References

• 1 van Leerdam ME, Vreeburg EM, Rauws EA et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003; 98: 1494-1499
  PubMedGoogle Scholar
• 2 Giday SA, Kim Y, Krishnamurty DM et al. Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model. Endoscopy 2011; 43: 296-299
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Giday S, Van Alstine W, Van Vleet J et al. Safety analysis of a hemostatic powder in a porcine model of acute severe gastric bleeding. Dig Dis Sci 2013; 58: 3422-3428
  CrossrefPubMedGoogle Scholar
• 4 Holster IL, Kuipers EJ, Tjwa ET. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45: 63-66
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Chen YI, Barkun AN, Soulellis C et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
  CrossrefPubMedGoogle Scholar
• 6 Holster IL, Poley JW, Kuipers EJ et al. Controlling gastric variceal bleeding with endoscopically applied hemostatic powder (Hemospray). J Hepatol 2012; 57: 1397-1398
  CrossrefPubMedGoogle Scholar
• 7 Holster IL, Brullet E, Kuipers EJ et al. Hemospray treatment is effective for lower gastrointestinal bleeding. Endoscopy 2014; 46: 75-78
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Smith LA, Stanley AJ, Bergman JJ et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-e92
  CrossrefPubMedGoogle Scholar
• 9 Walsh PN. The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Br J Haematol 1972; 22: 393-405
  CrossrefPubMedGoogle Scholar
• 10 Gordy SD, Rhee P, Schreiber MA. Military applications of novel hemostatic devices. Expert Rev Med Devices 2011; 8: 41-47
  CrossrefPubMedGoogle Scholar
• 11 Sena MJ, Douglas G, Gerlach T et al. A pilot study of the use of kaolin-impregnated gauze (Combat Gauze) for packing high-grade hepatic injuries in a hypothermic coagulopathic swine model. J Surg Res 2013; 183: 704-709
  CrossrefPubMedGoogle Scholar
• 12 Gebauer S, Hoopes D, Finlay E. From the battlefield to the palliative care arsenal: application of QuickClot Combat Gauze for aggressive palliation of hemorrhagic shock in the setting of end-stage liver disease-associated compartment syndrome. J Pain Symptom Manage 2013; 46: e6-e8
  PubMedGoogle Scholar
• 13 Margolis J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J Physiol 1958; 144: 1-22
  PubMedGoogle Scholar
• 14 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-219
  CrossrefPubMedGoogle Scholar
• 15 Kheirabadi BS, Scherer MR, Estep JS et al. Determination of efficacy of new hemostatic dressings in a model of extremity arterial hemorrhage in swine. J Trauma 2009; 67: 450-459
  CrossrefPubMedGoogle Scholar
• 16 Monroe DM, Hoffman M. What does it take to make the perfect clot?. Arterioscler Thromb Vasc Biol 2006; 26: 41-48
  CrossrefPubMedGoogle Scholar
• 17 Ranstam J. Reporting laboratory experiments. Osteoarthritis cartilage 2010; 18: 3-4
  CrossrefPubMedGoogle Scholar